Claritas Pharmaceuticals, Inc.
CLAZF · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -2,315.39% | -1,553.18% | -1,626.78% | -485.60% |
| EV / EBITDA | -0.33 | -0.12 | 0.02 | -0.02 |
| Quality | ||||
| ROIC | 482.39% | -39.08% | -21.64% | -22.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.07 | 0.31 | -0.70 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 95.23% | -33.73% | 12.82% | -239.91% |
| Safety | ||||
| Net Debt / EBITDA | -0.33 | -0.07 | 0.00 | 0.05 |
| Interest Coverage | -14.56 | -45.22 | -72.56 | -0.90 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |